CUT

Research Notes

A synthetic analog of growth hormone-releasing hormone, structurally modified for extended stability. It is the most clinically validated compound in the IRIX lineup, having undergone Phase III trials and carrying regulatory approval in some jurisdictions for a specific clinical indication. What the research explores: visceral adipose tissue reduction through pulsatile GH stimulation, lipid metabolism and cardiovascular risk marker changes, and why visceral fat responds differently to GH-mediated signaling than subcutaneous fat. What it isn't: a generalized fat-loss compound. The research specifically distinguishes visceral fat outcomes from total body fat or muscle-building effects, and the evidence base is narrower than its name recognition suggests.